Home LiteratureArticle Details

PMID: 2503769 Published · ppublish English Clinical Trial Comparative Study Journal Article Research Support, Non-U.S. Gov't

Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease.

Neurology ·Vol. 39 ·No. 8 ·1989-08-00 ·Pages 1109-11

Golbe LI

Abstract

Twenty-two patients with advanced Parkinson's disease whose symptom fluctuations had initially responded to deprenyl supplementation were followed for 19 to 27 months on that drug. The improvement disappeared in most cases after a mean of 7-8 months but persists at latest follow-up in 5 patients. Transient or continuing abnormalities in liver function tests occurred in 9 patients.

MeSH Terms

Adult Aged Analysis of Variance Clinical Enzyme Tests Clinical Trials as Topic Double-Blind Method Humans Liver/drug effects Liver Function Tests Middle Aged Parkinson Disease/drug therapy Phenethylamines/administration & dosage Safety Selegiline/administration & dosage,adverse effects Time Factors

Chemicals

Phenethylamines Selegiline

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Golbe L I

Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick 08903.

Article Info

Journal

Neurology

Abbr.

Neurology

ISSN

0028-3878

DOI

10.1212/wnl.39.8.1109

Published

1989-08-00

Pages

1109-11

Language

English

Region

United States

NLM ID

0401060

Subset

External Links

PubMed source DOI: 10.1212/wnl.39.8.1109 View journal details

Analysis Services

Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease.

Contact

WeChat Official Account